Latest news
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination…
Debiopharm to unveil new pre-clinical and clinical research advances in DDR inhibition, dual payload ADCs, and AI-driven biomarkers at AACR…
Released by Repare Therapeutics: Repare Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
Debiopharm Ignites Oncology Innovation with Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago
Debiopharm to Reveal Insights from their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at The 2025 AACR Conference in…
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…
MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1…
Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego